glp 1 drugs thyroid cancer Increased screening may lead to higher risk after GLP-1 initiation Ozempic: EU Sees No Evidence

Evaluate the benefits and concerns surrounding GLP-1 treatments

The Medicines and Healthcare products Regulatory Agency (MHRA) has warned healthcare professionals to be aware of the potential risk of pulmonary aspiration in patients using glucagon-like peptide-1 (GLP-1) or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (GLP-1 RAs), who undergo surgery or procedures with general anaesthesia or deep sedation

Clear communication and transparency between distributors and consumers will play a critical role in supporting informed decision-making and maintaining trust as these therapies become more widely available

Nausea is one of the most common side effects of GLP-1 medications

What if it doesnt work for me?

They stimulate insulin secretion and inhibit glucagon secretion by elevating e...